Bebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb - Research Grade
Source
CAS 2578319-11-4
Species
Homo sapiens
Molecular weight
143.8kDa
Purity
>85%
Buffer
PBS buffer PH7.5
Delivery condition
Blue ice (+4°C)
Delivery lead time in business days
3-5 days if in stock; 3-5 weeks if production needed
Delivery Time
3-5 days if in stock; 3 week if production needed
Storage condition
store at -80°C
Brand
ProteoGenix
Aliases /Synonyms
Bebtelovimab,LY-CoV1404, LY3853113,SARS-CoV-2 Spike Protein,anti-SARS-CoV-2 Spike Protein
Reference
PX-TA1750
Note
For research use only. Not suitable for human use.
Isotype
IgG1,kappa
Clonality
Monoclonal Antibody
Description of Bebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb - Research Grade
Title: Understanding Bebtelovimab Biosimilar: An Anti-SARS-CoV-2 Spike Protein mAb for Research
Introduction
Bebtelovimab Biosimilar is a monoclonal antibody (mAb) that specifically targets the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This biosimilar is a promising therapeutic option for treating COVID-19, the respiratory illness caused by SARS-CoV-2. In this article, we will delve into the structure, activity, and potential applications of Bebtelovimab Biosimilar in research.
Structure of Bebtelovimab Biosimilar
Bebtelovimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody, meaning it is derived from human antibody sequences and has been modified to reduce immunogenicity. It has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab region is responsible for binding to the target antigen, while the Fc region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Activity of Bebtelovimab Biosimilar
Bebtelovimab Biosimilar targets the spike protein of SARS-CoV-2, which is essential for viral entry into host cells. The spike protein consists of two subunits, S1 and S2, with the receptor-binding domain (RBD) located in the S1 subunit. The RBD is responsible for binding to the angiotensin-converting enzyme 2 (ACE2) receptor on human cells, facilitating viral entry. Bebtelovimab Biosimilar binds to the RBD of the spike protein, preventing it from interacting with the ACE2 receptor and thereby blocking viral entry.
In addition to direct neutralization of the virus, Bebtelovimab Biosimilar also has the potential to activate the immune system through its Fc region. This can lead to the recruitment of immune cells, such as natural killer cells and macrophages, to eliminate virus-infected cells. Furthermore, Bebtelovimab Biosimilar can also induce the production of cytokines, which are important for coordinating the immune response against the virus.
Applications in Research
Bebtelovimab Biosimilar is currently being studied as a potential therapeutic option for COVID-19. It is being evaluated in clinical trials for its safety and efficacy in treating patients with mild to moderate symptoms of COVID-19. Additionally, Bebtelovimab Biosimilar is also being investigated as a prophylactic treatment for high-risk individuals, such as healthcare workers, to prevent infection with SARS-CoV-2.
Apart from its potential therapeutic applications, Bebtelovimab Biosimilar also has potential research uses. The antibody can be used in laboratory experiments to study the interaction between the spike protein and the ACE2 receptor, as well as the mechanisms of viral entry and neutralization. It can also be used to develop diagnostic tests for SARS-CoV-2, such as enzyme-linked immunosorbent assays (ELISAs) and lateral flow assays, to detect the presence of the virus or antibodies against it in patient samples.
Conclusion
In conclusion, Bebtelovimab Biosimilar is a promising anti-SARS-CoV-2 spike protein mAb that has the potential to be used as a therapeutic agent and research tool. Its specific targeting of the spike protein and potential immunomodulatory effects make it a valuable addition to the fight against COVID-19. With ongoing research and clinical trials, Bebtelovimab Biosimilar may prove to be a crucial weapon in our arsenal against the current pandemic.
SDS-PAGE for Bebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb
Bebtelovimab Biosimilar - Anti-SARS-CoV-2 Spike Protein mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Publication
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike, Sieglinde De Cae, Inge Van Molle, Loes van Schie, Sophie R. Shoemaker, Julie Deckers, Nincy Debeuf, Sahine Lameire, Wim Nerinckx, Kenny Roose, Daria Fijalkowska, Simon Devos, Anne-Sophie Desmet, Jackeline Cecilia Zavala Marchan, Toon Venneman, Koen Sedeyn, Marlies Ballegeer, Manon Vanheerswynghels, Caroline De Wolf, Hans Demol, Pieter Vanhaverbeke, Gholamreza Hassanzadeh Ghassabeh, Chiara Lonigro, Viki Bockstal, Manuela Rinaldi, Rana Abdelnabi, Johan Neyts, Susan Marqusee, Bart N. Lambrecht, Nico Callewaert, Han Remaut, Xavier Saelens, Bert Schepens, bioRxiv 2023.03.10.531533; doi: https://doi.org/10.1101/2023.03.10.531533
Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including XBB.1.5 and BQ.1.1, Kevin C. Entzminger, Jonathan K. Fleming, Paul D. Entzminger, Lisa Yuko Espinosa, Alex Samadi, Yuko Hiramoto, CJ Okumura, Toshiaki Maruyama, bioRxiv 2023.01.25.525589; doi: https://doi.org/10.1101/2023.01.25.525589
Melissa García-Vega, Edgar A. Melgoza-González, Sofía Hernández-Valenzuela, Harold Marcotte, Qiang Pan-Hammarström, Jesús Hernández et al., 19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern, iScience, Volume 26, ISSUE 4, 106562, April 21, 2023, https://doi.org/10.1016/j.isci.2023.106562
Fiaschi, L.; Biba, C.; Varasi, I.; Bartolini, N.; Paletti, C.; Giammarino, F.; Saladini, F.; Zazzi, M.; Vicenti, I. In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants. Viruses 2024, 16, 168. https://doi.org/10.3390/v16020168
De Cae, S., Van Molle, I., van Schie, L. et al. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base. Nat Commun 16, 5040 (2025). https://doi.org/10.1038/s41467-025-60250-1
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Bebtelovimab Biosimilar – Anti-SARS-CoV-2 Spike Protein mAb – Research Grade” Cancel reply
Reviews
There are no reviews yet.